Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Brian Kavanagh to Radiosurgery

This is a "connection" page, showing publications Brian Kavanagh has written about Radiosurgery.

 
Connection Strength
  
 
 
11.938
  
  1. Kavanagh BD. The Economics of Using Locally Ablative Therapy in Oligometastatic Cancer. Semin Radiat Oncol. 2021 07; 31(3):250-252.
    View in: PubMed
    Score: 0.563
  2. Mohideen N, Kavanagh BD. Model Insurance Coverage Policies: The Power of Suggestion, the Force of Evidence. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):745-747.
    View in: PubMed
    Score: 0.491
  3. Sheehan JP, Grills I, Chiang VL, Dong H, Berg A, Warnick RE, Kondziolka D, Kavanagh B. Quality of life outcomes for brain metastasis patients treated with stereotactic radiosurgery: pre-procedural predictive factors from a prospective national registry. J Neurosurg. 2019 12 01; 131(6):1848-1854.
    View in: PubMed
    Score: 0.473
  4. Rusthoven CG, Jones BL, Kavanagh BD. Medical operability and inoperability drive survival in retrospective analyses comparing surgery and SBRT for early-stage lung cancer. J Thorac Cardiovasc Surg. 2018 02; 155(2):810-811.
    View in: PubMed
    Score: 0.444
  5. Rusthoven CG, Kavanagh BD. Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise. J Thorac Oncol. 2017 12; 12(12):1746-1754.
    View in: PubMed
    Score: 0.432
  6. Rusthoven CG, Palma DA, Senan S, Kavanagh BD. The Head Start Effect: Will Acute and Delayed Postoperative Mortality Lead to Improved Survival with Stereotactic Body Radiation Therapy for Operable Stage I Non-Small-Cell Lung Cancer? J Clin Oncol. 2017 05 20; 35(15):1749-1751.
    View in: PubMed
    Score: 0.416
  7. Goodman KA, Kavanagh BD. Stereotactic Body Radiotherapy for Liver Metastases. Semin Radiat Oncol. 2017 07; 27(3):240-246.
    View in: PubMed
    Score: 0.416
  8. Kavanagh BD. From the Guest Editor: New Lenses, New Visions for Radiotherapy in the Molecular-Genetic-Immunomodulator Era of Oncology. Cancer J. 2016 Jul-Aug; 22(4):245-6.
    View in: PubMed
    Score: 0.398
  9. Kavanagh BD. Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes. J Clin Oncol. 2014 Sep 10; 32(26):2827-31.
    View in: PubMed
    Score: 0.349
  10. Stinauer MA, Diot Q, Westerly DC, Schefter TE, Kavanagh BD. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):e613-8.
    View in: PubMed
    Score: 0.297
  11. Schefter TE, Kavanagh BD. Radiation therapy for liver metastases. Semin Radiat Oncol. 2011 Oct; 21(4):264-70.
    View in: PubMed
    Score: 0.286
  12. Kavanagh BD, Timmerman R, Meyer JL. The expanding roles of stereotactic body radiation therapy and oligofractionation: toward a new practice of radiotherapy. Front Radiat Ther Oncol. 2011; 43:370-381.
    View in: PubMed
    Score: 0.279
  13. Kavanagh BD, Miften M, Rabinovitch RA. Advances in treatment techniques: stereotactic body radiation therapy and the spread of hypofractionation. Cancer J. 2011 May-Jun; 17(3):177-81.
    View in: PubMed
    Score: 0.278
  14. Kavanagh BD, Newman F. Toward a unified survival curve: in regard to Park et al. (IntJ Radiat Oncol Biol Phys 2008;70:847-852) and Krueger et al. (Int J Radiat Oncol Biol Phys 2007;69:1262-1271). Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):958-9.
    View in: PubMed
    Score: 0.229
  15. Timmerman RD, Park C, Kavanagh BD. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol. 2007 Jul; 2(7 Suppl 3):S101-12.
    View in: PubMed
    Score: 0.213
  16. Kavanagh BD, Kelly K, Kane M. The promise of stereotactic body radiation therapy in a new era of oncology. Front Radiat Ther Oncol. 2007; 40:340-351.
    View in: PubMed
    Score: 0.206
  17. Kavanagh BD, Scheftera TE, Wersäll PJ. Liver, renal, and retroperitoneal tumors: stereotactic radiotherapy. Front Radiat Ther Oncol. 2007; 40:415-426.
    View in: PubMed
    Score: 0.206
  18. Kavanagh BD, Ding M, Schefter TE, Stuhr K, Newman FA. The dosimetric effect of inhomogeneity correction in dynamic conformal arc stereotactic body radiation therapy for lung tumors. J Appl Clin Med Phys. 2006 May 25; 7(2):58-63.
    View in: PubMed
    Score: 0.198
  19. Poznanovic SA, Cass SP, Kavanagh BD. Short-term tumor control and acute toxicity after stereotactic radiosurgery for glomus jugulare tumors. Otolaryngol Head Neck Surg. 2006 Mar; 134(3):437-42.
    View in: PubMed
    Score: 0.194
  20. Kavanagh BD, Timmerman RD. Stereotactic radiosurgery and stereotactic body radiation therapy: an overview of technical considerations and clinical applications. Hematol Oncol Clin North Am. 2006 Feb; 20(1):87-95.
    View in: PubMed
    Score: 0.193
  21. Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, McCarter MD, Burri S, Nedzi LA, Sawyer TE, Gaspar LE. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006; 45(7):848-55.
    View in: PubMed
    Score: 0.192
  22. Pike LRG, Miao E, Boe LA, Patil T, Imber BS, Myall NJ, Pollom EL, Hui C, Qu V, Langston J, Chiang V, Grant M, Goldberg SB, Palmer JD, Prasad RN, Wang TJC, Lee A, Shu CA, Chen LN, Thomas NJ, Braunstein SE, Kavanagh BD, Camidge DR, Rusthoven CG. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC). J Clin Oncol. 2024 Oct 20; 42(30):3606-3617.
    View in: PubMed
    Score: 0.174
  23. Rusthoven CG, Staley AW, Gao D, Yomo S, Bernhardt D, Wandrey N, El Shafie R, Kraemer A, Padilla O, Chiang V, Faramand AM, Palmer JD, Zacharia BE, Wegner RE, Hattangadi-Gluth JA, Levy A, Bernstein K, Mathieu D, Cagney DN, Chan MD, Grills IS, Braunstein S, Lee CC, Sheehan JP, Kluwe C, Patel S, Halasz LM, Andratschke N, Deibert CP, Verma V, Trifiletti DM, Cifarelli CP, Debus J, Combs SE, Sato Y, Higuchi Y, Aoyagi K, Brown PD, Alami V, Niranjan A, Lunsford LD, Kondziolka D, Camidge DR, Kavanagh BD, Robin TP, Serizawa T, Yamamoto M. Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE). J Natl Cancer Inst. 2023 08 08; 115(8):926-936.
    View in: PubMed
    Score: 0.163
  24. Kavanagh BD, Timmerman RD, Benedict SH, Wu Q, Schefter TE, Stuhr K, McCourt S, Newman F, Cardinale RM, Gaspar LF. How should we describe the radioblologic effect of extracranial stereotactic radlosurgery: equivalent uniform dose or tumor control probability? Med Phys. 2003 Mar; 30(3):321-4.
    View in: PubMed
    Score: 0.158
  25. Milano MT, Soltys SG, Marks LB, Heron DE, Yorke E, Grimm J, Jackson A, Mihai A, Timmerman RD, Xue J, Kavanagh BD, Redmond KJ. The Art of Radiation Therapy: The Necessary Risk of Radiation Necrosis for Durable Control of Brain Metastases. Int J Radiat Oncol Biol Phys. 2023 02 01; 115(2):294-296.
    View in: PubMed
    Score: 0.155
  26. Das IJ, Dawes SL, Dominello MM, Kavanagh B, Miyamoto CT, Pawlicki T, Santanam L, Vinogradskiy Y, Yeung AR. Quality and Safety Considerations in Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy: An ASTRO Safety White Paper Update. Pract Radiat Oncol. 2022 Jul-Aug; 12(4):e253-e268.
    View in: PubMed
    Score: 0.148
  27. Grimm J, Marks LB, Jackson A, Kavanagh BD, Xue J, Yorke E. High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview. Int J Radiat Oncol Biol Phys. 2021 05 01; 110(1):1-10.
    View in: PubMed
    Score: 0.139
  28. Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, Yomo S, Aiyama H, Higuchi Y, Shuto T, Akabane A, Sato Y, Niranjan A, Faramand AM, Lunsford LD, McInerney J, Tuanquin LC, Zacharia BE, Chiang V, Singh C, Yu JB, Braunstein S, Mathieu D, Touchette CJ, Lee CC, Yang HC, Aizer AA, Cagney DN, Chan MD, Kondziolka D, Bernstein K, Silverman JS, Grills IS, Siddiqui ZA, Yuan JC, Sheehan JP, Cordeiro D, Nosaki K, Seto T, Deibert CP, Verma V, Day S, Halasz LM, Warnick RE, Trifiletti DM, Palmer JD, Attia A, Li B, Cifarelli CP, Brown PD, Vargo JA, Combs SE, Kessel KA, Rieken S, Patel S, Guckenberger M, Andratschke N, Kavanagh BD, Robin TP. Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study. JAMA Oncol. 2020 07 01; 6(7):1028-1037.
    View in: PubMed
    Score: 0.131
  29. Stumpf PK, Cittelly DM, Robin TP, Carlson JA, Stuhr KA, Contreras-Zarate MJ, Lai S, Ormond DR, Rusthoven CG, Gaspar LE, Rabinovitch R, Kavanagh BD, Liu A, Diamond JR, Kabos P, Fisher CM. Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4. Clin Cancer Res. 2019 07 01; 25(13):3946-3953.
    View in: PubMed
    Score: 0.120
  30. Weiss J, Kavanagh B, Deal A, Villaruz L, Stevenson J, Camidge R, Borghaei H, West J, Kirpalani P, Morris D, Lee C, Pecot CV, Zagar T, Stinchcombe T, Pennell N. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treat Res Commun. 2019; 19:100126.
    View in: PubMed
    Score: 0.120
  31. Robin TP, Breeze RE, Smith DE, Rusthoven CG, Lewis KD, Gonzalez R, Brill A, Saiki R, Stuhr K, Gaspar LE, Karam SD, Raben D, Kavanagh BD, Nath SK, Liu AK. Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. J Neurooncol. 2018 Oct; 140(1):55-62.
    View in: PubMed
    Score: 0.114
  32. Robin TP, Jones BL, Amini A, Koshy M, Gaspar LE, Liu AK, Nath SK, Kavanagh BD, Camidge DR, Rusthoven CG. Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer. Lung Cancer. 2018 06; 120:88-90.
    View in: PubMed
    Score: 0.112
  33. Stokes WA, Bronsert MR, Meguid RA, Blum MG, Jones BL, Koshy M, Sher DJ, Louie AV, Palma DA, Senan S, Gaspar LE, Kavanagh BD, Rusthoven CG. Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 03 01; 36(7):642-651.
    View in: PubMed
    Score: 0.111
  34. Miften M, Vinogradskiy Y, Moiseenko V, Grimm J, Yorke E, Jackson A, Tomé WA, Ten Haken RK, Ohri N, Méndez Romero A, Goodman KA, Marks LB, Kavanagh B, Dawson LA. Radiation Dose-Volume Effects for Liver SBRT. Int J Radiat Oncol Biol Phys. 2021 05 01; 110(1):196-205.
    View in: PubMed
    Score: 0.111
  35. Sheehan J, Suh JH, Kavanagh B, Xu Z, Ren L, Sheehan K, Lunsford LD. Training Neurosurgery and Radiation Oncology Residents in Stereotactic Radiosurgery: Assessment Gathered from Participants in AANS and ASTRO Training Course. World Neurosurg. 2018 Jan; 109:e669-e675.
    View in: PubMed
    Score: 0.109
  36. Trifiletti DM, Sheehan JP, Grover S, Dutta SW, Rusthoven CG, Kavanagh BD, Sahgal A, Showalter TN. National trends in radiotherapy for brain metastases at time of diagnosis of non-small cell lung cancer. J Clin Neurosci. 2017 Nov; 45:48-53.
    View in: PubMed
    Score: 0.108
  37. Kim DN, Straka C, Cho LC, Lotan Y, Yan J, Kavanagh B, Raben D, Cooley S, Brindle J, Xie XJ, Pistenmaa D, Timmerman R. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial. Pract Radiat Oncol. 2017 Jan - Feb; 7(1):e43-e49.
    View in: PubMed
    Score: 0.099
  38. Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh BD, Brindle J, Raben D, Nanda A, Cooley S, Kim DWN, Pistenmaa D, Lotan Y, Timmerman R. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer. 2016 05; 59:142-151.
    View in: PubMed
    Score: 0.098
  39. Zhao J, Yorke ED, Li L, Kavanagh BD, Li XA, Das S, Miften M, Rimner A, Campbell J, Xue J, Jackson A, Grimm J, Milano MT, Spring Kong FM. Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. Int J Radiat Oncol Biol Phys. 2016 Aug 01; 95(5):1357-1366.
    View in: PubMed
    Score: 0.098
  40. Diot Q, Kavanagh B, Vinogradskiy Y, Garg K, Gaspar L, Miften M. Lung deformations and radiation-induced regional lung collapse in patients treated with stereotactic body radiation therapy. Med Phys. 2015 Nov; 42(11):6477-87.
    View in: PubMed
    Score: 0.095
  41. Altoos B, Amini A, Yacoub M, Bourlon MT, Kessler EE, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol. 2015 Oct 28; 10:218.
    View in: PubMed
    Score: 0.095
  42. Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. J Clin Oncol. 2016 Jan 10; 34(2):123-9.
    View in: PubMed
    Score: 0.095
  43. Sheehan JP, Kavanagh BD, Asher A, Harbaugh RE. Inception of a national multidisciplinary registry for stereotactic radiosurgery. J Neurosurg. 2016 Jan; 124(1):155-62.
    View in: PubMed
    Score: 0.094
  44. Chetty IJ, Martel MK, Jaffray DA, Benedict SH, Hahn SM, Berbeco R, Deye J, Jeraj R, Kavanagh B, Krishnan S, Lee N, Low DA, Mankoff D, Marks LB, Ollendorf D, Paganetti H, Ross B, Siochi RA, Timmerman RD, Wong JW. Technology for Innovation in Radiation Oncology. Int J Radiat Oncol Biol Phys. 2015 Nov 01; 93(3):485-92.
    View in: PubMed
    Score: 0.093
  45. Amini A, Altoos B, Bourlon MT, Bedrick E, Bhatia S, Kessler ER, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? Pract Radiat Oncol. 2015 Nov-Dec; 5(6):e589-e596.
    View in: PubMed
    Score: 0.093
  46. Bourlon MT, Amini A, Kavanagh BD, Flaig TW. Pancreatic metastases from renal cell carcinoma treated with stereotactic body radiation therapy. Oncology (Williston Park). 2014 Nov; 28(11):1008-12.
    View in: PubMed
    Score: 0.089
  47. Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014 Dec 01; 32(34):3824-30.
    View in: PubMed
    Score: 0.089
  48. Amini A, Yeh N, Gaspar LE, Kavanagh B, Karam SD. Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. Radiat Oncol. 2014 Sep 19; 9:210.
    View in: PubMed
    Score: 0.088
  49. Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, Kavanagh B, Kabos P. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol. 2014 Jul; 16(7):1006-9.
    View in: PubMed
    Score: 0.087
  50. Kim DW, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, Kavanagh BD, Nanda A, Kueplian P, Brindle J, Cooley S, Perkins A, Raben D, Xie XJ, Timmerman RD. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 01; 89(3):509-17.
    View in: PubMed
    Score: 0.087
  51. Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, Camidge DR. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):892-8.
    View in: PubMed
    Score: 0.084
  52. Jones BL, Gan G, Kavanagh B, Miften M. Effect of endorectal balloon positioning errors on target deformation and dosimetric quality during prostate SBRT. Phys Med Biol. 2013 Nov 21; 58(22):7995-8006.
    View in: PubMed
    Score: 0.083
  53. Altunbas C, Kavanagh B, Dzingle W, Stuhr K, Gaspar L, Miften M. Dosimetric errors during treatment of centrally located lung tumors with stereotactic body radiation therapy: Monte Carlo evaluation of tissue inhomogeneity corrections. Med Dosim. 2013; 38(4):436-41.
    View in: PubMed
    Score: 0.082
  54. Vinogradskiy Y, Diot Q, Kavanagh B, Schefter T, Gaspar L, Miften M. Spatial and dose-response analysis of fibrotic lung changes after stereotactic body radiation therapy. Med Phys. 2013 Aug; 40(8):081712.
    View in: PubMed
    Score: 0.081
  55. Westerly DC, Schefter TE, Kavanagh BD, Chao E, Lucas D, Flynn RT, Miften M. High-dose MVCT image guidance for stereotactic body radiation therapy. Med Phys. 2012 Aug; 39(8):4812-9.
    View in: PubMed
    Score: 0.076
  56. Howells CC, Stinauer MA, Diot Q, Westerly DC, Schefter TE, Kavanagh BD, Miften M. Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):e441-6.
    View in: PubMed
    Score: 0.075
  57. Jones BL, Gan G, Diot Q, Kavanagh B, Timmerman RD, Miften M. Dosimetric and deformation effects of image-guided interventions during stereotactic body radiation therapy of the prostate using an endorectal balloon. Med Phys. 2012 Jun; 39(6):3080-8.
    View in: PubMed
    Score: 0.075
  58. Diot Q, Kavanagh B, Schefter T, Gaspar L, Stuhr K, Miften M. Regional normal lung tissue density changes in patients treated with stereotactic body radiation therapy for lung tumors. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):1024-30.
    View in: PubMed
    Score: 0.075
  59. Diot Q, Kavanagh B, Timmerman R, Miften M. Biological-based optimization and volumetric modulated arc therapy delivery for stereotactic body radiation therapy. Med Phys. 2012 Jan; 39(1):237-45.
    View in: PubMed
    Score: 0.073
  60. Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011 Apr 08; 6:34.
    View in: PubMed
    Score: 0.069
  61. Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, Schefter TE. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011 Sep 01; 117(17):4060-9.
    View in: PubMed
    Score: 0.069
  62. Heinzerling JH, Kavanagh B, Timmerman RD. Stereotactic ablative radiation therapy for primary lung tumors. Cancer J. 2011 Jan-Feb; 17(1):28-32.
    View in: PubMed
    Score: 0.068
  63. Fields EC, Damek D, Gaspar LE, Liu AK, Kavanagh BD, Waziri A, Lillehei K, Chen C. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):51-7.
    View in: PubMed
    Score: 0.067
  64. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tomé WA, Verellen D, Wang L, Yin FF. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010 Aug; 37(8):4078-101.
    View in: PubMed
    Score: 0.066
  65. Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, Mehta MP, Ryu S, Steinberg M, Timmerman R, Welsh JS, Rosenthal SA. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):326-32.
    View in: PubMed
    Score: 0.064
  66. Dunlap NE, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K, Schefter TE, Kavanagh BD, Larner JM. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):796-801.
    View in: PubMed
    Score: 0.061
  67. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009 Apr 01; 27(10):1579-84.
    View in: PubMed
    Score: 0.060
  68. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009 Apr 01; 27(10):1572-8.
    View in: PubMed
    Score: 0.060
  69. Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 2009; 48(4):578-83.
    View in: PubMed
    Score: 0.059
  70. Olsen CC, Welsh J, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, Gaspar LE, Schefter TE. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1414-24.
    View in: PubMed
    Score: 0.059
  71. McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):112-8.
    View in: PubMed
    Score: 0.058
  72. Solberg TD, Kavanagh BD, Medin PM. Stereotactic body radiation therapy: a new paradigm in radiotherapy management of cancer. J Am Coll Radiol. 2008 May; 5(5):673-7.
    View in: PubMed
    Score: 0.057
  73. Schwer AL, Damek DM, Kavanagh BD, Gaspar LE, Lillehei K, Stuhr K, Chen C. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2008 Mar 15; 70(4):993-1001.
    View in: PubMed
    Score: 0.055
  74. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007 Mar 10; 25(8):947-52.
    View in: PubMed
    Score: 0.052
  75. Timmerman R, Abdulrahman R, Kavanagh BD, Meyer JL. Lung cancer: a model for implementing stereotactic body radiation therapy into practice. Front Radiat Ther Oncol. 2007; 40:368-385.
    View in: PubMed
    Score: 0.052
  76. Song DY, Kavanagh BD, Benedict SH, Schefter T. Stereotactic body radiation therapy. Rationale, techniques, applications, and optimization. Oncology (Williston Park). 2004 Oct; 18(11):1419-30; discussion 1430, 1432, 1435-6.
    View in: PubMed
    Score: 0.044
  77. Eley KW, Benedict SH, Chung TD, Kavanagh BD, Broaddus WC, Schmidt-Ullrich RK, Lin PS. The effects of pentoxifylline on the survival of human glioma cells with continuous and intermittent stereotactic radiosurgery irradiation. Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):542-50.
    View in: PubMed
    Score: 0.038
  78. Manning MA, Cardinale RM, Benedict SH, Kavanagh BD, Zwicker RD, Amir C, Broaddus WC. Hypofractionated stereotactic radiotherapy as an alternative to radiosurgery for the treatment of patients with brain metastases. Int J Radiat Oncol Biol Phys. 2000 Jun 01; 47(3):603-8.
    View in: PubMed
    Score: 0.033
  79. Cardinale RM, Wu Q, Benedict SH, Kavanagh BD, Bump E, Mohan R. Determining the optimal block margin on the planning target volume for extracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 1999 Sep 01; 45(2):515-20.
    View in: PubMed
    Score: 0.031
  80. Robin TP, Camidge DR, Stuhr K, Nath SK, Breeze RE, Pacheco JM, Liu AK, Gaspar LE, Purcell WT, Doebele RC, Kavanagh BD, Rusthoven CG. Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 05; 13(5):715-720.
    View in: PubMed
    Score: 0.028
  81. Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. J Clin Oncol. 2017 Apr 01; 35(10):1070-1077.
    View in: PubMed
    Score: 0.026
  82. Høyer M, Swaminath A, Bydder S, Lock M, Méndez Romero A, Kavanagh B, Goodman KA, Okunieff P, Dawson LA. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):1047-57.
    View in: PubMed
    Score: 0.018
  83. Schwer AL, Kavanagh BD, McCammon R, Gaspar LE, Kleinschmidt-De Masters BK, Stuhr K, Chen C. Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1352-7.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)